NEO (NeoGenomics) Cyclically Adjusted Revenue per Share: $4.84 (As of Mar. 2026)


NEO NeoGenomics Inc NEO
72 GF Score
Price $14.73
GF Value $16.63
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Cyclically Adjusted Revenue per Share?

NeoGenomics NEO +3.41% 72 Cyclically Adjusted Revenue per Share is $4.84 as of Mar. 2026. GuruFocus rates NEO with a GF Score™ of 72/100 and a GF Value™ of $16.63 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NeoGenomics's adjusted revenue per share for the three months ended in Mar. 2026 was $1.445. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.84 for the trailing ten years ended in Mar. 2026.

During the past 12 months, NeoGenomics's average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of NeoGenomics was 24.50% per year. The lowest was 11.40% per year. And the median was 18.05% per year.

As of today (2026-07-09), NeoGenomics's current stock price is $14.725. NeoGenomics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $4.84. NeoGenomics's Cyclically Adjusted PS Ratio of today is 3.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NeoGenomics was 23.86. The lowest was 1.14. And the median was 5.94.


NeoGenomics  (NAS:NEO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NeoGenomics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=14.725/4.84
=3.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NeoGenomics was 23.86. The lowest was 1.14. And the median was 5.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NeoGenomics Cyclically Adjusted Revenue per Share Related Terms


NeoGenomics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Cyclically Adjusted Revenue per Share Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.97 3.41 3.83 4.26 4.72

NeoGenomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.40 4.52 4.64 4.72 4.84

NEO vs WGS, CDNA, PSNL: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted PS Ratio falls into.


NEO
72GF Score
NeoGenomics Inc NEO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NeoGenomics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.445/330.2130*330.2130
=1.445

Current CPI (Mar. 2026) = 330.2130.

NeoGenomics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.815 241.018 1.117
201609 0.778 241.428 1.064
201612 0.614 241.432 0.840
201703 0.730 243.801 0.989
201706 0.784 244.955 1.057
201709 0.743 246.819 0.994
201712 0.767 246.524 1.027
201803 0.788 249.554 1.043
201806 0.751 251.989 0.984
201809 0.760 252.439 0.994
201812 0.793 251.233 1.042
201903 1.009 254.202 1.311
201906 0.994 256.143 1.281
201909 0.970 256.759 1.247
201912 1.007 256.974 1.294
202003 1.015 258.115 1.299
202006 0.806 257.797 1.032
202009 1.052 260.280 1.335
202012 1.013 260.474 1.284
202103 0.994 264.877 1.239
202106 0.928 271.696 1.128
202109 0.990 274.310 1.192
202112 1.026 278.802 1.215
202203 0.948 287.504 1.089
202206 1.008 296.311 1.123
202209 1.035 296.808 1.151
202212 1.112 296.797 1.237
202303 1.098 301.836 1.201
202306 1.172 305.109 1.268
202309 1.209 307.789 1.297
202312 1.235 306.746 1.329
202403 1.239 312.332 1.310
202406 1.301 314.175 1.367
202409 1.322 315.301 1.385
202412 1.353 315.605 1.416
202503 1.319 319.799 1.362
202506 1.417 322.561 1.451
202509 1.462 324.800 1.486
202512 1.478 324.054 1.506
202603 1.445 330.213 1.445

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.84 mean?
NeoGenomics (NEO) has a Cyclically Adjusted Revenue per Share of $4.84 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Cyclically Adjusted Revenue per Share too high?
NeoGenomics' current Cyclically Adjusted Revenue per Share is $4.84. Overall, NeoGenomics has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Cyclically Adjusted Revenue per Share compare to WGS and CDNA?
NeoGenomics' Cyclically Adjusted Revenue per Share of $4.84 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on NeoGenomics and its competitors. NeoGenomics's current Cyclically Adjusted Revenue per Share is $4.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.63, compared to a current price of $14.73 — trading 11.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.84. NeoGenomics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For NeoGenomics (NEO), the current Cyclically Adjusted Revenue per Share is $4.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of $14.73 is trading 11.5% below its estimated GF Value™ of $16.63. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for NEO:

  • Cyclically Adjusted Revenue per Share: $4.84
  • GF Value™: $16.63 vs. price of $14.73 (11.5% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeoGenomics Business Description

Other Exchanges NEO:MexicoNG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
72GF Score

Get the complete analysis for NEO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.73
Price
$16.63
GF Value